摘要
目的 :探讨急性非淋巴细胞性白血病 (ANL L)患者乳腺癌耐药蛋白 (BCRP)基因表达与临床耐药的关系。方法 :应用半定量反转录—聚合酶链反应 (RT- PCR)并以 β2 微球蛋白 (β2 - MG)作内对照 ,检测了 36例 ANL L 患者及 10例非恶性血液病对照组患者 BCRP基因的表达 ,将 BCRP/β2 - MG≥ 0 .5定为 BCRP阳性。结果 :BCRP基因在急性白血病中 ,阳性表达高 ,表达水平差别较大 ,由低到高依次为 :对照组、完全缓解组、初治敏感组和临床耐药组。其中临床耐药组 BCRP基因表达水平显著高于对照组、完全缓解组 (P值分别为 <0 .0 2 5 ,P<0 .0 5 ) ;初治敏感组高于对照组 (P<0 .0 5 )。 ANL L BCRP基因表达似与 FAB分型无关 ,但与常用髓系单抗有关 (P<0 .0 5 )。结论 :BCRP基因在急性白血病中阳性表达率较高 ,BCRP基因过度表达可能导致 ANL L临床耐药 ,是 AN-L
Objective:To investigate the relationship between the expression of BCRP gene and drug resistance in patients with ANLL β 2 MG was used as a internal referance.BCRP/β 2 MG ratio≥0.5 was defined as BCRP positive.Methods:Semi quantitative reverse transcriptase polymerase chain reaction (RT PCR) was used to examine the expression of BCRP gene in ANLL patients and 10 patients with non maligance hematology disease as a control.β 2 microglobin (β was correlated with common myeloid clusters of differentiation (CD) ( P <0.05).Results:The positive percentage of BCRP gene expression in patients with ANLL was elevated.The expression level of BCRP gene was more variation and arranged in the order of magnitude was as follows:control group,complete remission (CR) group,newly diagnosed/drug sensitive group and relapsed/refractory group.The expression level of BCRP mRNA and the positive percentage of BCRP in relapased/refractory group was significantly higher than that in control group and than that in CR group ( P <0.005 and P <0.05 respectively).The level in newly diagnosed/drug sensitive group was significantly higher than that in control group ( P <0.05).There was no any relationship between the expression of BCRP gene in ANLL patients and that in FAB subtypes,but the level of BCRP mRNA expression.Conclusion:ANLL patients are of elevated expression of BCRP gene.The excessive expression of that might induce drug resistance and might be an unfavorable factor for ANLL patients.
出处
《白血病．淋巴瘤》
CAS
2002年第3期139-142,共4页
Journal of Leukemia & Lymphoma
关键词
急性非淋巴细胞性白血病
乳腺癌耐药蛋白
逆转录-聚合酶链反应
预后
基因表达
Acute non lymphocytic leukemia
Breast cancer resisitance protein
Reverse transcriptase polymerase chain reaction
Prognosis
Gene expression
